Treatment guidelines recommend neoadjuvant or adjuvant therapies with surgery for patients with large primary tumors or clinical evidence of intrathoracic nodal spread.1,2 A recent joint IASLC–U.S. Food and Drug Administration […] Read more
By Sylvie Lantuejoul, MD, PhD, and Mari Mino-Kenudson, MD Posted: April 16, 2020 Immune checkpoint inhibitors (ICI), which target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity, are […] Read more
By Lynette M. Sholl, MD, and John W. Longshore, PhD, FACMG Posted: February 12, 2020 Dr. Lynette M. Sholl Dr. John W. Longshore The profound impact of immunotherapy in patients […] Read more
By Anjali Saqi, MD, MBA; Deepali Jain, MD, FIAC; Lukas Bubendorf, MD; Keith Kerr, MB, ChB, MRCPath, FRCPath, FRCP(Ed); and Andre Moreira, MD, PhD Posted: December 11, 2019 Lung cancer […] Read more
By Mari Mino-Kenudson, MD, and Sylvie Lantuejoul, MD, PhD Posted: November 12, 2019 Determination of PD-L1 expression by immunohistochemistry (IHC) has been widely evaluated in clinical trials as a predictive […] Read more
By Ignacio Wistuba, MD, and John Minna, MD Posted: August 14, 2019 Dr. Adi Gazdar was a scientific pioneer, a groundbreaking pathologist, a loyal friend, and an inspiring mentor. Dr. Gazdar […] Read more
By Anja C. Roden, MD, and Natasha Rekhtman, MD, PhD Posted: May 27, 2019 Dr. Anja C. Roden Pulmonary neuroendocrine tumors are classified according to the World Health Organization into typical […] Read more
By Andre L. Moreira, MD Posted: April 1, 2019 Most of the progress in thoracic oncology is in the treatment of patients with NSCLC. The determination of subtypes of NSCLC, namely […] Read more
By Keith M. Kerr, BSc, MB, ChB, FRCPath, FRCPE Posted: March 1, 2019 There was a time, remembered by us older pathologists, when the image of pathology was that of a […] Read more
By Doreen A. Ezeife, MD, FRCPC; Malcolm Ryan; and Natasha B. Leighl, MD, MMSc, FRCPC, FASCO Posted: March 1, 2019 Dramatic improvements in lung cancer outcomes can be attributed to […] Read more